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Mesenchymal stromal cells (MSCs) have been isolated from many tissues, including gestational tissue. To date, a
study comparing the properties and suitability of these cells in cell-based therapies is lacking. In this study, we
compared the phenotype, proliferation rate, migration, immunogenicity, and immunomodulatory capabilities of
human MSCs derived from umbilical cord lining (CL-MSCs), umbilical cord blood (CB-MSCs), placenta
(P-MSCs), and Wharton’s jelly (WJ-MSCs). Differences were noted in differentiation, proliferation, and migra-
tion, with CL-MSCs showing the highest proliferation and migration rates resulting in prolonged survival in
immunodeficient mice. Moreover, CL-MSCs showed a prolongation in survival in xenogeneic BALB/c mice,
which was attributed to their ability to dampen TH1 and TH2 responses. Weaker human cellular immune
responses were detected against CL-MSCs and P-MSCs, which were correlated with their lower HLA I ex-
pression. Furthermore, HLA II was upregulated less substantially by CL-MSCs and CB-MSCs after IFN-g
stimulation. MSC types did not differ in indolamine 2,3-dioxygenase (IDO) expression after IFN-g stimulation.
Despite their lower IDO, HLA-G, and TGF-b1 expression, only CL-MSCs were able to reduce the release of IFN-g
by lymphocytes in a mixed lymphocyte reaction. In summary, CL-MSCs showed the best characteristics for cell-
based strategies, as they are hypo-immunogenic and show high proliferation and migration rates. In addition,
these studies show for the first time that although immunomodulatory molecules HLA-G, HLA-E, and TGF-b
play an important role in MSC immune evasion, basal and induced HLA expression seems to be decisive in
determining the immunogenicity of MSCs.
Introduction
Mesenchymal stromal cells (MSCs) have in the lastdecade gained considerable attention as candidates for
tissue regeneration [1] and as modulators of immune re-
sponses in graft-versus-host-disease [2], in prolonging sur-
vival of solid organ transplants [3,4], and as modulators of
autoimmune diseases [5]. There is evidence that MSCs mod-
ulate the immune response by inhibiting T-cell activation,
proliferation, and function [6–8], NK cell proliferation and
cytotoxicity [9,10], as well as B cell proliferation and differ-
entiation [11]. Moreover, MSCs can activate various immu-
nosuppressive mechanisms by inducing regulatory T-cells
[12] or directing dendritic cells to a tolerogenic phenotype
1Transplant and Stem Cell Immunobiology Lab, University Heart Center Hamburg, Hamburg, Germany.
2Cardiovascular Research Center (CVRC), DZHK University Hamburg, Hamburg, Germany.
3Department of Cardiothoracic Surgery, Falk Cardiovascular Research Center, Stanford University School of Medicine, Stanford,
California.
4Department of Surgery, Yong Loo Lin School of Medicine and Centre for Craniofacial and Regenerative Biology, Clinical Research
Center, National University of Singapore and CellResearch Corporation, Singapore, Singapore.
5Faculty of Clinical Medicine Mannheim, Institute of Transfusion Medicine and Immunology, German Red Cross Blood Service of
Baden-Wu¨rttemberg-Hessen, University of Heidelberg, Mannheim, Germany.
6Adult Stem Cell Laboratory, Mater Medical Research Institute, South Brisbane, Australia.
7School of Medicine, University of Queensland, St. Lucia, Australia.
8HLA Lab, Institute for Transfusion Medicine, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
9Department of Pathology, University Erlangen, Erlangen, Germany.
10Department of Anatomy and Experimental Morphology, University Hospital Hamburg, Hamburg, Germany.
11Institute of Medical Immunology and Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charite´—University Medicine
Berlin, Berlin, Germany.
STEM CELLS AND DEVELOPMENT
Volume 22, Number 19, 2013
 Mary Ann Liebert, Inc.
DOI: 10.1089/scd.2013.0043
2619
[13]. Additionally, an interesting veto-effect exerted on T-cells
in a mixed lymphocyte reaction (MLR) by MSCs has also been
described [14,15]. The feasibility of allogeneic MSC therapies
for tissue or organ regeneration rests on the concept that MSCs
avoid or actively suppress the immunological responses that
cause rejection of most allogeneic cells and tissues [16]. Ulti-
mately, successful allogeneic cell therapies will rely on an im-
proved understanding of the parameters of MSC–immune
system interactions in vivo [16,17] and studies are needed to
identify the most suitable source for MSC generation.
To date, most research on MSCs has concentrated on bone
marrow-derived cells (BM-MSCs); however, they are not an
ideal source for cellular therapy, as their isolation is associ-
ated with donor morbidity and, even more importantly, the
number of MSCs found in the bone marrow and their re-
generative potential significantly declines with age [18,19].
On the other hand, MSCs have also been isolated from ex-
traembryonic gestational tissues such as the placenta [20] (P-
MSC), umbilical cord lining [15] (CL-MSC), cord blood [21]
(CB-MSC), and Wharton’s jelly [22] (WJ-MSC). Due to the
young chronological age of the donor, these cells are devoid
of mutations and their isolation is noninvasive and so safe to
both the infant and mother [23]. Furthermore, in our previ-
ous study, we showed that CL-MSCs were superior to BM-
MSCs in their immunomodulatory capabilities and their
hypo-immunogenicity [15]. In our present study, we com-
pared the proliferation rates, migration capabilities, immu-
nogenicity, and multiple immunomodulatory mechanisms
exhibited by MSCs from four extraembryonic gestational
tissues: CL-MSCs, CB-MSCs, P-MSCs, and WJ-MSCs. The
results of this study have given insight into the mechanisms
involved in MSC-mediated immunomodulation and more
importantly, have allowed to identify the MSC type most
suitable for cell-based therapies.
Materials and Methods
Extraembryonic gestational tissue-derived MSC
isolation and morphology
CL-MSCs were isolated as previously described [24] and
cultured in the PTT4 medium (CellResearch Corporation).
CB-MSCs were isolated and cultured in the low-glucose
DMEM +GlutaMAX-1 and Pyruvate supplemented with
MSCGM SingleQuots (Lonza) [21]. P-MSCs were isolated as
described by Barlow et al. and cultured in the low-glucose
DMEM +GlutaMAX-1 and Pyruvate supplemented with
20% heat inactivated fetal calf serum and gentamicin [20].
WJ-MSCs were obtained from Thermo Scientific and cul-
tured in the AdvanceSTEM Mesenchymal Stem Cell Basal
Medium supplemented with AdvanceSTEM Mesenchymal
Stem Cell Growth Supplement (Thermo Scientific) and 1%
penicillin–streptomycin or the Human Mesenchymal Stem
Cell Expansion Medium (CET) supplemented with 10 ng/
mL recombinant human FGF (PeproTech). The low-glucose
DMEM, fetal calf serum, and penicillin–streptomycin were
all obtained from Gibco, Invitrogen. About 0.1% gelatin
(Millipore)-coated culture flasks (SARSTEDT AG & Co.)
were used for P-MSCs and WJ-MSCs.
All cells were cultured at 37C in a humidified atmosphere
of 95% air and 5% CO2 until 70%–80% confluency before
trypsinization (TrypLE Express, Gibco, Invitrogen) or being
removed by scraping with a cell scraper (Falcon BD Bios-
ciences) (for FACS, MTS, and western blot analysis).
Scratch assay
MSCs were plated in 0.1% gelatin-coated (Millipore) six-
well plates (Falcon; BD Biosciences) (1· 106 cells/well). A
scratch in the confluent cell monolayer was made with a
pipette tip (P200) and after 6 h, cells were fixed with 10%
PFA (paraformaldehyde) (Electron Microscopy Sciences) and
washed with PBS (Gibco). Phase-contrast images were ac-
quired using a Leica microscope and QWin acquisition
software (Leica Microsysteme Vertrieb GmbH) (magnifica-
tion 100 · ). Migrated cells in 3–4 segments of the scratch
area (300 · 500 mm each) were counted. Each analysis was
performed 10 times.
Cell proliferation assay
Cells were seeded in a 96-well flat-bottom plate (Nunc)
(4,000 cells/well) and incubated at 37C in 5% humidified
CO2. The medium was changed every second day and cell
counts were quantified every day for 4 consecutive days
using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium, (MTS) assay
(CellTiter 96 Aqueous One Solution Cell Proliferation Assay;
Promega). Absorbance at 490 nm was measured with the
Magellan ELISA Reader and Software (Tecan Systems, Inc.).
Differentiation assays
For adipocyte and osteocyte differentiation, cells were
plated in 24-well plates (6 · 104 cells/well) (Falcon, BD
Biosciences) in a growth medium and incubated at 37C in
5% humidified CO2. After 24 h, the culture medium was
changed to the appropriate differentiation medium (Promo-
Cell GmbH). For chondrocyte differentiation, cells were
plated in 96-well suspension plates (SARSTEDT AG & Co)
(1 · 105 cells/well in 200mL). The differentiation medium was
changed three times per week for 21 days or 14 days (adi-
pocytes). Cells were stained for adipocyte (Oil Red O and
hematoxylin counterstaining), chondrocyte (Toluidine Blue),
and osteocyte (Alizarin Red S) differentiation as previously
described [15]. Images were acquired using a Leica micro-
scope and QWin acquisition software (Leica Microsysteme
Vertrieb GmbH).
Flow cytometry
Cells were labeled with phycoerythrin (PE)-conjugated
antibodies against human: CD31 (clone WM59), CD34 (clone
563), CD44 (clone G44-26C26), CD45 (clone H130), CD90
(clone 5E10), CD117/c-Kit (clone 104D2), HLA-ABC (clone
DX17), TRA-1–60 (clone TRA-1–60) (all from BD Bios-
ciences), HLA-DR +DP +DQ (clone WR18; Abcam), SSEA-4
(clone MCB13–70), and CD105 (clone 166707) (all R&D Sys-
tems). Unconjugated antibodies: HLA-E (clone MEM-E/06;
Santa Cruz Biotechnologies) and HLA-G (clone MEM-G/9;
Santa Cruz Biotechnologies) were visualized using PE-
conjugated anti-mouse IgG1a or IgG2a (both Santa Cruz
Biotechnologies). Mouse isotype matched antibodies IgG1,
IgG2a, IgM (clones: MOPC-21, MOPC-173, and G155–228,
respectively; all BD Biosciences), and IgG3 (clone 133316;
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R&D Systems) were used as controls. Data were acquired on a
FACSCalibur flow cytometer using CellQuest Pro software
(all BD Biosciences) and analyzed using FlowJo version 7.2.5
software (Tree Star). The results were expressed as folds of the
isotype control. The data are shown as the mean from three
independent experiments. Recombinant human IFN-g (25 ng/
ml; PeproTech) was added to the cell culture medium for 48 h
before flow cytometry, where indicated.
Indolamine 2,3-dioxygenase detection
Cellular proteins were extracted using the RIPA buffer
supplemented with Protease Inhibitor Cocktail according to
the manufacturer’s instructions (both Sigma-Aldrich). Protein
concentrations were measured using the Pierce BCA Protein
Assay Kit (Thermo Scientific). Ten microgram protein per well
was loaded on a NuPAGE Novex 4%–12% Bis-Tris Gel and
separated using the NuPAGE Bis-Tris Electrophoresis system
(Invitrogen). Proteins were transferred onto a 0.2mm PVDF
membrane (Invitrogen), where indolamine 2,3-dioxygenase
(IDO) (clone: H-110; Santa Cruz Biotechnologies) or GAPDH
(clone: 14C10; Cell Signaling Technology) were detected using
unconjugated antibodies. After an overnight incubation step,
horseradish peroxidase-conjugated antibodies (Amersham
Biosciences) were used to detect bound rabbit monoclonal
antibodies. Antigens were identified with the ECL plus a
western blotting detection kit (Amersham Biosciences) and
imaged with the IVIS 200 system (Xenogen, Caliper Life-
systems). Blots were stripped with the restore western blot
stripping buffer (Pierce, Thermo Scientific) before being re-
probed for the housekeeping GAPDH. For IDO induction,
500 ng/mL recombinant human IFN-g (PeproTech) was ad-
ded to the cell culture medium for 48 h.
ELISA
Human IL-2, IL-10, and TGF-b1 were detected in cell culture
supernatants using the BD OptEIA ELISA sets and BD OptEIA
Reagent SET B according to the manufacturer’s instructions (BD
Biosciences). Cells were cultured at a density of 2.7·104 cells/
cm2 for 48 h before the cell culture supernatant was collected
and stored at -20C. The data are shown as mean from three
independent experiments, after normalization to their cell
counts using the MTS assay and presented as (pg/mL)/OD.
Animals
Six- to 8-week-old male BALB/c mice were purchased from
Charles River Laboratories and housed under specific pathogen-
free conditions in the animal care facilities of the University
Hamburg, and received humane care in compliance with Uni-
versity guidelines. Animals were randomly assigned to one of the
four study groups and received either CL-MSC, CB-MSC, P-MSC,
or WJ-MSC transplantations (n=6 per group) by intramuscular
injection of 1.0·106 firefly luciferase (fLuc)-positive MSCs.
MSC lentiviral transduction
Cells were made to express fLuc under the CMV promoter
by transducing with pLenti CMV Puro fLuc (w168-1) [25]
(Addgene plasmid 17477). Transduction efficiency was en-
hanced by adding 8 mg/mL polybrene (Sigma-Aldrich Cor-
poration) into the cell culture medium. Stable transfectants
were enriched by puromycin (Santa Cruz Biotechnologies)
selection at 0.08 mg/mL (CL-MSC, P-MSC, and WJ-MSC) or
0.5 mg/mL (CB-MSC). To estimate transduction efficiency,
the cells were tested for the fLuc activity in a cell number
titration assay. For bioluminescence imaging (BLI), 9.1 mg D-
luciferin was dissolved in 10 mL PBS pH 7.4 (Gibco, In-
vitrogen) and added into each confluent cell flask.
Bioluminescence in vivo imaging
For BLI, D-luciferin firefly, potassium salt (375 mg/kg)
(Biosynth AG) dissolved in PBS pH 7.4 (Gibco, Invitrogen) was
injected intraperitonealy (200mL per mouse) into anesthetized
mice (2% isoflorane; Forene, Abbot GmbH & Co. KG). Animals
were imaged using the IVIS 200 system (Xenogen). Region of
interest (ROI) bioluminescence was quantified in units of
maximum photons per second per centimeter square per ster-
idian (p/s/cm2/sr). The maximum signal from an ROI
was measured using Living Image 3.1 software (Media-
Cybernetics).
Rejection of MSCs in vivo
To test the rejection of MSCs, in vivo 1.0· 106 fLuc-positive
CL-MSCs, CB-MSCs, P-MSCs, or WJ-MSCs in 60mL PBS
(Gibco, Invitrogen) were injected into the hind limb muscle of
immunocompetent BALB/c mice. FLuc expression was ex-
amined on days 0, 1, and thereafter, every second day until
the signal dropped to background levels; n= 6/group.
In vivo ELISPOT assay in BALB/c mice
To test the immunogenicity of MSCs in vivo, 1· 106 MSCs
in 60mL PBS (Gibco, Invitrogen) were injected into the gas-
trocnemius muscle of BALB/c mice. Spleens were harvested
after 5 days and 1 · 107 splenocytes were used as responder
cells with 1· 106 mitomycin C treated-MSCs (Sigma Aldrich)
as stimulators, to detect anti-mouse IL-4 and IFN-g in an
ELISPOT assay (BD Biosciences).
In vitro human ELISPOT assay
To test the potential of MSCs to modify the immune re-
sponse of human peripheral blood mononuclear cells
(PBMCs), 5 · 106 Ficoll-isolated (Ficoll-Paque PLUS solution,
Amersham Biosciences) PBMCs were used as responder cells
with 1 · 105 MSCs. Anti-human IL-4 and IFN-g responses
were detected in a 4-day ELISPOT assay (BD Biosciences).
The immunosuppressive properties of MSCs in vitro were
assessed by their potential to suppress a one-directional al-
logeneic mixed lymphocyte response in an allogeneic setting.
A total of 5 · 106 allogeneic Ficoll-isolated (Amersham Bio-
sciences) human PBMCs was used as responder cells with
5· 105 mitomycin C-treated (Sigma Aldrich) PBMCs and
1· 105 MSCs. Anti-human IFN-g responses were detected in
a 4-day ELISPOT assay (BD Biosciences). All ELISPOT spots
were counted using an ELISPOT plate reader (CTL).
Statistical analysis
Data are presented as the mean – standard deviation.
Comparisons were done by analysis of variance between
groups with Fisher’s least significant difference Post Hoc
tests. Probability values ( p) of less than 0.05 were considered
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significant. Statistical analysis was performed using the SPSS
statistical software package 15.0 for Windows (SPSS, Inc.).
Results
Characterization of extraembryonic gestational
tissue-derived MSCs
All four cell types adhered to plastic and were spindle
shaped (Fig. 1A). To further verify that the cells were MSCs,
we tested for the expression of typical MSC markers, in-
cluding CD44, CD90, and CD105 (Supplementary Fig. S1A;
Supplementary Data are available online at www.liebertpub
.com/scd). All four cell types were highly positive for these
markers and negative for endothelial (CD31), hematopoietic
lineage (CD34 and CD45), and pluripotent stem cell (CD117,
TRA-1–60) markers. Flow cytometry also revealed almost no
expression of HLA class II or costimulatory molecules; CD80,
CD86, and CD40 (data not shown). Interestingly, SSEA-4,
which is associated with MSCs derived from the bone mar-
row [26] was expressed by all cells.
To confirm multipotency of the cells, we tried to differ-
entiate them into osteocytes, chondrocytes, and adipocytes
(Supplementary Fig. S1B). In accordance with previous
studies CB-MSC [27] and P-MSC [20] did not readily differ-
entiate into cells of the adipogenic lineage. In our hands also,
WJ-MSCs did not show adipogenic differentiation within the
3-week time frame.
In summary, our data support the notion that only CL-
MSCs fulfill the criteria for MSCs according to the criteria of
the International Society for Cellular Therapy [28].
Migratory and proliferative potential
of extraembryonic gestational tissue-derived MSCs
We evaluated the migration capabilities of MSCs in a
scratch assay. CL-MSCs were able to migrate into the scratch
area the fastest (P < 0.001 compared to CB-MSCs, P-MSCs,
and WJ-MSCs) (Figs. 1B, C). CB-MSCs showed a slightly
lower level of migratory potential, but were still faster than
P-MSCs (P < 0.001) and WJ-MSCs (P < 0.001). P-MSCs and
WJ-MSCs demonstrated the lowest migratory potential, with
the least cells entering the scratch area after 6 h.
To investigate whether the MSCs differed in their prolifer-
ation potential, we compared them in a MTS assay. CL-MSCs
showed a significantly higher proliferation rate than P-MSCs
and WJ-MSCs (P< 0.01; Fig. 1D).
Immunogenicity and survival of MSCs
The fLuc signal correlated with cell numbers after
transduction (Supplementary Figs. S2 and S3). The ability of
MSCs to evade a xenogeneic immune response in vivo was
elucidated in immunocompetent BALB/c mice (Fig. 2A).
FLuc positive CL-MSCs were detected up to 11 days after
injection, while both P-MSCs and WJ-MSCs were rejected by
day 7 (P < 0.01 and P< 0.01 for CL-MSCs versus P-MSCs and
WJ-MSCs, respectively). The fLuc signal of CB-MSCs was
detected until day 9 in BALB/c mice. To test whether the
differences in MSC survival in immunocompetent mice were
due to their ability to evoke T helper (TH)1 or TH2 responses,
ELISPOT assays were performed 5 days after MSC injection
into BALB/c mice (Figs. 2B, C). CL-MSCs evoked the
weakest immune response of TH1 cells (IFN-g: P < 0.001,
P < 0.002, P < 0.005 compared to CB-MSCs, P-MSCs, and WJ-
MSCs, respectively), and TH2 (IL-4 assays: all P < 0.001
compared to CB-MSCs, P-MSCs, and WJ-MSCs). CB-MSCs,
P-MSCs, and WJ-MSCs evoked a similar cell-mediated im-
mune response.
To further investigate the immunogenicity of MSCs, ELI-
SPOT assays using human allogeneic PBMCs as responders
were carried out. CB-MSCs and WJ-MSCs provoked the
strongest cellular responses for TH1 cells (Fig. 2D) (both
P < 0.001). Interestingly, WJ-MSCs induced a significant TH1
immune response, despite having the least HLA mismatches
with the PBMC responder A (Supplementary Table S1). Both
CL-MSCs and P-MSCs showed a weak alloresponse only.
The number of IL-4 secreting PBMCs was comparable
among cell types and only differed between CB-MSCs and
P-MSCs (P < 0.05) (Fig. 2E).
Next, we investigated whether distinct immunogenicity
might be related to HLA expression of the MSCs from dif-
ferent sources. In our study, native CL-MSCs and CB-MSCs
expressed quite low, while P-MSCs and WJ-MSCs expressed a
moderate level of HLA class I molecules on their surface (Fig.
3A). We also determined whether the presence of IFN-g, as-
sociated with inflammation, increases the level of HLA class I
expression, which would lead to an increase in MSC immu-
nogenicity and ultimately make MSCs more susceptible to T-
cell-mediated lysis. A 48-h stimulation period with a moderate
concentration of IFN-g lead to an increase in surface expres-
sion of HLA class I by all MSC types to quite similar levels,
except P-MSCs (P< 0.001, P< 0.005, and P< 0.02 for CL-MSCs,
CB-MSCs, and WJ-MSCs, respectively).
All native MSCs showed a very low HLA class II ex-
pression before the addition of IFN-g (Fig. 3B). IFN-g (25 ng/
mL) induced the upregulation in HLA II expression in all
MSCs (P < 0.01 for both CL-MSCs and CB-MSCs, P < 0.001 for
both P-MSCs and WJ-MSCs). WJ-MSCs showed the highest
expression level after stimulation (P < 0.001 for all MSC types
versus WJ-MSCs).
Immunomodulation by MSCs
HLA-G expression is associated with the immunosup-
pressive phenotype of MSCs [29,30]. The upregulation of
surface HLA-G in the presence of IFN-g with the exception of
CB-MSCs (P < 0.001) was not significant (Fig. 4A). Differ-
ences in expression were, however, observed among the
MSC types studied (P < 0.02 CL-MSCs versus CB-MSCs and
P < 0.05 for CB-MSCs versus P-MSCs).
In addition, MSCs express the NK cell ligand HLA-E (Fig.
4B) [29]. HLA-E upregulation by IFN-g reached significance
only in CB-MSCs (P < 0.001).
It has been demonstrated that IDO plays an important role
in mediating the suppressive effect of MSCs on T-cells [31].
IDO, which is involved in the catabolism of tryptophan, an
essential amino acid crucial for T-cell proliferation [32], was
not detected in native MSCs (Fig. 4C). However, all MSC
types showed a similar degree of IDO upregulation after a
48-h stimulation period with 500 ng/mL of IFN-g, which in
our experiments mimicked an inflammatory milieu.
In our previous study [15], we showed that resting CL-
MSCs released IL-10 and TGF-b1 and that the release of both
cytokines could be increased with IFN-g stimulation. In our
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present study, we quantified the amount of cytokines re-
leased by MSCs using an ELISA assay. IL-10 and IL-2 were
not detected in the conditioned supernatants from resting
MSCs (assay detection limit 7.8 pg/mL) (data not shown),
while TGF-b1 was secreted by all MSCs (detection limit
125 pg/mL) (Fig. 4D). After normalization to their cell count,
P-MSCs secreted the highest amount of TGF-b1 compared to
other MSCs (P < 0.05).
The immunomodulatory effect of MSCs on T-cells can be
demonstrated in a one-way MLR [14,15]. For this assay, we
FIG. 1. Extraembryonic gestational tissue-derived MSC morphology, migratory, and proliferative potential. (A) Phase-
contrast images show that all MSCs are spindle shaped and plastic adherent. Scale bar: 100 mm. (B) Phase-contrast images of
MSCs show the scratch area at 0 (top panel) and 6 h thereafter (lower panel). The rectangle represents the scratch area
(300 · 500mm). Scale bar: 200 mm. (C) Quantified scratch assay data showing the mean number of migrated cells into the
scratch area after 6 h. CL-MSCs migrated into the scratch area significantly faster than the other MSC types. (D) CL-MSCs
showed a significantly higher proliferation capability in vitro than P-MSCs and WJ-MSCs, whereas there was no significant
difference in the observed proliferation between CB-MSCs and CL-MSCs. CB-MSCs showed a significantly higher prolif-
eration rate than P-MSCs. These differences were already significant by day 2. Graphs present the mean optical density (OD)
at 492 nm. Each analysis was performed in quadruples. (*P < 0.05; **P < 0.001). MSC, mesenchymal stromal cell; CL-MSC,
MSC derived from umbilical cord lining; CB-MSC, MSC derived from umbilical cord blood; P-MSC, MSC derived from
placenta; WJ-MSC, MSC derived from Wharton’s jelly.
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FIG. 2. Survival and immunogenicity of extraembryonic gestational tissue-derived MSCs (n=6/group). (A) The rejection profile
of fLuc-positive MSCs injected into immunocompetent BALB/c mice was monitored by bioluminescence imaging (BLI). P-MSCs,
WJ-MSCs, and CB-MSCs were rejected 7.0–1.3, 8.0–1.9, and 7.8–0.8 days after transplantation, whereas CL-MSC survival was
significantly longer (10.7–1.5 days; *P<0.05 vs. all other groups). Bioluminescence was quantified in units of maximum photons
per second per centimeter square per steridian (p/s/cm2/sr). The background (3.4·105 p/s) is shown as a solid black line. (B) To
detect murine IFN-g secreting cells 5 days after injecting 1·106 MSCs into BALB/c mice, splenocytes were used as responders in
an ELISPOT assay. Mice showed the lowest spot frequency with CL-MSCs. *P<0.05, **P<0.001. (C) Similarly, mice showed the
lowest IL-4 spot frequency with CL-MSCs, corresponding to a very mild immune response. **P<0.001. (D) ELISPOT using human
allogeneic PBMCs as responders showed that CB-MSCs and WJ-MSCs induced a strong IFN-g response compared to CL-MSCs
and P-MSCs. **P<0.001. (E) Only CB-MSCs and P-MSCs differed in the IL-4 response among all cell types. PBMCs, peripheral
blood mononuclear cells; fLuc, firefly luciferase.
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included mismatched donor and responder PBMCs, as well as
MSCs (for HLA-typing results, please refer to Supplementary
Table S1A, B). The number of IFN-g releasing human PBMCs
in response to allogeneic PBMCs was significantly increased
when CB-MSCs and WJ-MSCs were added (Fig. 4E; P< 0.025
and P< 0.001 compared to PBMCs A+B, respectively). CB-
MSCs and WJ-MSCs induced a significantly stronger IFN-g
response compared to CL-MSCs (P< 0.05 and P<0.001, re-
spectively). TH1 responses of WJ-MSC MLR was also signifi-
cantly higher than using P-MSCs (P< 0.002).
Discussion
To date, MSCs have been isolated from organs such as
bone marrow, liver, spleen [33,34], and adipose tissue [35].
MSCs derived from extraembryonic gestational tissue in
contrast to those mentioned above, show great promise in
MSC-based therapies. Their isolation is simple and does not
require any invasive procedures and typically involves the
isolation of cells from tissues discarded after birth. To iden-
tify the most suitable cell type for allogeneic cell-based
therapies, we compared the immunogenicity and immuno-
modulatory capabilities, as well as the proliferative and
migratory potential of MSCs isolated from different extra-
embryonic gestational tissues.
Although the cell types examined in our study fulfilled
most of the criteria accepted for MSCs [28], only CL-MSCs
were truly multipotent as they were able to differentiate into
adipocytes. Moreover, MSCs differed in terms of their cell
culture requirements. These differences could be explained
by the fact that the cells were isolated using different tech-
niques, from different extraembryonic tissue compartments,
and from different donors and from different laboratories.
MSC-type and donor-specific differences in adipocyte dif-
ferentiation have in the past been observed by other groups
[20,27]. It is conceivable that MSCs are not a homogenous
population and the tissue from which they are isolated dis-
tinguishes them [27,34,36] and directs their potential thera-
peutic use. This study aimed to determine whether the
extraembryonic gestational tissue-derived MSCs differed in
their suitability for cell-based therapy.
MSC migration plays a pivotal role in MSC-mediated
wound healing. Significant differences in migration rates
were observed between MSC types, showing CL-MSCs mi-
grating the fastest into the scratch area. Large numbers of
MSCs are needed for regenerative therapies, which promp-
ted us to examine whether the MSCs differed in their pro-
liferative potential in vitro. In this assay, CL-MSCs and
CB-MSCs showed the highest rates, making their ex vivo
expansion easier.
There is a growing body of evidence suggesting that MSCs
induce tolerance and so can survive in vivo for prolonged
periods of time in an allogeneic setting [37]. On the other
hand, previous studies have also suggested that allogeneic
FIG. 3. HLA I and II expression. (A) Native MSCs expressed a low to moderate level of HLA class I molecules (gray filled
histogram), which was increased after 25 ng/mL IFN-g was added to the cell culture for 48 h. HLA class I expression is noted
above each histogram. (B) HLA class II expression was increased significantly after incubation with 25 ng/mL IFN-g in all
MSC types. The results were expressed as folds of the isotype control.
GESTATIONAL TISSUE DERIVED MSCS 2625
FIG. 4. Immunomodulatory capabilities of extraembryonic gestational tissue-derived MSCs. (A) Native MSCs expressed
low levels of surface HLA-G. The addition of 25 ng/mL IFN-g to the cell cultures 24 h before flow cytometry revealed a
variable response among the MSCs, with only CB-MSCs significantly upregulating HLA-G. *P < 0.05, **P < 0.001. IFN-g,
interferon-g; (+ ) 25 ng/mL IFN-g. (B) The effect of IFN-g on HLA-E expression was more pronounced, with all MSCs except
P-MSCs upregulating HLA-E expression after stimulation. The results were expressed as folds of the isotype control.
**P < 0.001. IFN-g, interferon-g; (+ ) 25 ng/mL IFN-g. (C) Quantification of the immunoblot after IDO expression was nor-
malized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). No statistical significance was observed between groups
either in their baseline IDO expression or after IFN-g stimulation. (D) Transforming growth factor b1 (TGF-b1) was measured
in cell supernatants and normalized to their proliferation measured in OD. P-MSCs secreted the highest amount of TGF-b1.
*P < 0.05, **P < 0.001. (E) MSCs were added as a third-party cell in a one-way MLR using human PBMCs. PBMCs released
IFN-g in response to allogeneic PBMCs (control), which could be inhibited only by CL-MSCs. *P < 0.05, **P < 0.001. MLR,
mixed lymphocyte reaction; PBMCs, peripheral blood mononuclear cells. IDO, indolamine 2,3-dioxygenase.
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MSC transplantation can lead to the induction of immune
responses in the recipient and lead to the rejection of the
implanted cells [38]. In our present study, we demonstrated
the low immunogenicity of extraembryonic tissue-derived
MSCs and especially CL-MSCs. All MSCs showed a low to
moderate HLA class I, low HLA II, and no costimulatory
molecule expression. Therefore, we investigated the MSC
targeted xenogeneic immune response in vivo using immu-
nocompetent BALB/c mice. CL-MSCs, which showed the
latest rejection, demonstrated also the lowest TH1 and TH2
cell activation in our ELISPOT assay using BALB/c sensi-
tized splenocytes as responders. Similarly, when we used
human PBMCs as responders, the spot frequency was low,
which suggests that human CL-MSCs are able to limit mu-
rine as well as human immune responses. Interestingly, P-
MSCs although they induced a high xenogeneic response,
were able to limit human TH1 and TH2 cell activation. The
reason for this might be the absence of responsiveness to
human IFN-g (Fig. 3). In the murine system, the response to
IFN-g is missing as human MSCs are not reactive to mouse
IFN-g. Further studies should demonstrate the immunoge-
nicity of human MSCs in the mouse system under inflam-
matory (human IFN-g) conditions.
In our study, all MSC types increased HLA class I ex-
pression in the presence of a moderate concentration of IFN-
g. We expect that the reason for WJ-MSCs inducing a very
high IFN-g response in MLR assays is caused by their high
HLA class I and II expression.
The increase in MSC immunogenicity due to HLA I or II
upregulation could potentially be counter-balanced by vari-
ous immunomodulatory molecules, such as HLA-G, HLA-E,
or IDO, which can influence the recipient’s immune re-
sponses. Nonclassical HLA expression (HLA-G) has been
suggested in playing a role in MSCs evading immune re-
sponses [30]. More importantly, it has been shown that both
HLA-E and HLA-G expression, on the target cell are needed
for the inhibition of NK cell lysis [39]. Therefore, we com-
pared HLA-G and HLA-E expression among the different
types of MSCs with and without IFN-g stimulation. We
found that only CB-MSCs show a significant increase in both
HLA-G and HLA-E surface expression. However, all MSCs
studied were able to significantly upregulate IDO after a 48-h
stimulation period with high-dose IFN-g.
Since MSCs exert immunomodulatory effects not only via
direct cell–cell contact, but also by releasing soluble factors
such as IL-10 and TGF-b1 [40], a varied expression of these
factors will lead to differences in exerting immunosuppres-
sive effects. We found that P-MSCs released significant
amounts of TGF-b1.
In our hands, extraembryonic tissue-derived MSCs were
unable to weaken the immune reaction in MLRs. Indeed, CB-
MSCs and WJ-MSCs even significantly enhanced the release
of IFN-g by PBMCs. Similarly, human first trimester liver-
derived MSCs are unable to suppress an MLR, which has
been attributed to their immunological immaturity [41].
Contrary findings have been reported for second trimester
MSCs from gestational tissues, which suppress MLR re-
sponses in an IL-10-dependent manner [42]. In our study, we
investigated extraembryonic gestational tissue MSCs from
full-term births, which clearly differ from second trimester-
derived MSCs. The lack of MLR suppressive potential ob-
served here may be due to their low IL-10 release. Second
trimester MSCs from the fetal–maternal interface could be
better equipped to suppress an MLR. However, MSCs could
possibly lose this capability around the time of birth. Roelen
et al. reported that gestational tissue-derived MSCs of fetal
origin (amnion and amniotic fluid) show a stronger inhibi-
tion of MLRs compared to MSCs of maternal (decidua) ori-
gin [42]. In this study, MSCs from the umbilical blood and
cord were of fetal [23], whereas placental MSCs were of
maternal origin [20], which could possibly explain some of
the observed differences in our immunological assays.
Although CL-MSCs expressed only moderate levels of
HLA-G, HLA-E, and TGF-b1 and also did not differ in IDO
production from other MSCs, they showed the longest
in vivo survival rates and the lowest immune stimulation
in our xenogeneic murine and allogeneic human ELISPOT
assays. More importantly, these findings are further sup-
ported by the result of our human MLR as only CL-MSCs
slightly reduced the production of IFN-g by PBMCs in the
allo-response.
In summary, we found that extraembryonic gestational
tissue-derived MSC populations show a varied potential to
evade immune responses as well as exert immunomodulatory
effects. CL-MSCs showed the most promising potential for a
cell-based therapy, as the cells showed low immunogenicity,
but they also showed enhanced proliferative and migratory
potential. Future research should concentrate on the best
disease models in which CL-MSCs could be administered.
Furthermore, our study highlights that although immuno-
modulatory molecules play an important role in MSC immune
evasion, HLA expression is in some way related to the im-
munogenicity of MSCs, and therefore basal and induced
HLA-expression should be examined when choosing suitable
cell types for cell-based off-the-shelf therapies.
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